Most of oral targeted therapies are tyrosine kinase inhibitors (TKIs). Oral administration
generates a complex step in the pharmacokinetics (PK) of these drugs. Inter-individual PK …

Thanks to their anti-inflammatory, anti-oedema, and anti-allergy properties, glucocorticoids
are among the most widely prescribed drugs in patients with cancer. The indications for …

In this review article, we will first provide a brief overview of the ErbB receptor–ligand system
and its importance in developmental and physiological processes. We will then review the …

Since the approval of the first molecularly targeted tyrosine kinase inhibitor (TKI), imatinib, in
2001, TKIs have heralded a new era in the treatment of many cancers. Among their …

The treatment of many malignancies has been improved in recent years by the introduction
of molecular targeted therapies. These drugs interact preferentially with specific targets that …

Background Erlotinib shows large inter-patient pharmacokinetic variability, but the impact of
early drug exposure and genetic variations on the clinical outcomes of erlotinib remains fully …

Objectives Gefitinib is a potent epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor and is a key drug for patients with EGFR mutation-positive advanced non-small cell …

Rationale Tyrosine kinase inhibitors are increasingly used in the treatment of cancer. Drug
interactions involving tyrosine kinase inhibitors are commonly encountered in clinical …

Inhaled chemotherapy was first used more than 30 years ago. Since then, numerous
chemotherapeutic agents have been used in either in vitro or in vivo studies. Several …

Pulmonary toxicity is a known complication of erlotinib, one of the epidermal growth factor
receptor tyrosine kinase inhibitors. It consists of diverse entities such as interstitial …